Understanding perspectives of asthma among pulmonologists in Indian settings: results from a questionnaire-based survey
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20234136Keywords:
Asthma, ICS-LABA, Maintenance and reliever therapy, Compliance surveyAbstract
Background: Asthma is associated with high morbidity and mortality in India. This survey was undertaken to explore the perspectives of pulmonologists towards in-clinic management of patients with asthma.
Methods: It was a cross-sectional survey of pulmonologists conducted across India. It was formulated to provide unbiased observations of real-world clinical practice focusing on methods of diagnosis of asthma and its treatment preferences.
Results: The participants included 805 pulmonologists, with the majority primarily treating patients with asthma (62%), chronic obstructive pulmonary disease (19%) and allergic rhinitis (19%). More than 86% of pulmonologists consider clinical symptoms, history of childhood asthma, family history, and chronic allergic rhinitis for initial diagnosis. About 19-23% prefer spirometry alone or in combination with family history for confirmation of asthma. The preferred inhaled corticosteroids-long-acting bronchodilator (ICS-LABA) combination was budesonide-formoterol amongst 83% of pulmonologists. For both dry powder inhaler (DPI) and metered dose inhaler (MDI) devices, fine particle fraction per cent and delivered dose were ranked as the two most important attributes.
Conclusions: Asthma is the most prevalent diagnosis among patients treated by pulmonologists on the basis of clinical presentation and medical history. The most commonly used pharmacotherapy for the treatment of asthma comprises ICS-LABA, with budesonide-formoterol being the preferred combination. Fine particle fraction per cent and magnitude of delivered dose influence the choice of asthma inhaler prescriptions the most.
Metrics
References
Sharma BB, Singh S, Sharma KK, Sharma AK, Suraj KP, Mahmood T, et al. Proportionate clinical burden of respiratory diseases in Indian outdoor services and its relationship with seasonal transitions and risk factors: The results of SWORD survey. PLoS One. 2022;17(8):e0268216.
Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis. 2012;16(9):1270-7.
Global Burden of Diseases Compare. Institute for Health Metrics and Evaluation. Viz Hub, 2021. Available at: https://vizhub.healthdata.org/gbd-compare/. Accessed 16 August 2022.
Singh S, Salvi S, Mangal DK, Singh M, Awasthi S, Mahesh PA, et al. Prevalence, time trends and treatment practices of asthma in India: The Global Asthma Network study. ERJ Open Res. 2022;8(2):00528-2021.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. Available at: https://ginasthma.org/. Accessed 02 December 2022.
Kavanagh J, Jackson DJ, Kent BD. Over- and under-diagnosis in asthma. Breathe (Sheff). 2019;15(1):e20-7.
Acevedo-Prado A, Seoane-Pillado T, López-Silvarrey-Varela A, Salgado FJ, Cruz MJ, Faraldo-Garcia A, et al. Association of rhinitis with asthma prevalence and severity. Sci Rep. 2022;12(1):6389.
Zhang B, Li ZF, An ZY, Zhang L, Wang JY, Hao MD, Jin YJ, et al. Association between asthma and all-cause mortality and cardiovascular disease morbidity and mortality: a meta-analysis of cohort studies. Front Cardiovasc Med. 2022;9:861798.
Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martínez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007;61(5):725-36.
Kuna P. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged >or =16 years with asthma: post hoc analysis of a randomized, double-blind study. Clin Drug Investig. 2010;30:565-79.
Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs. 2004;64:1597-618.
Jiang P, Zhao L, Yao Z. Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis. J Comp Eff Res. 2021;10(17):1283-9.
Vogelmeier C, Naya I, Ekelund J. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study. Clin Drug Investig. 2012;32:439-49.
Sadatsafavi M, FitzGerald JM, O'Byrne PM, Soliman M, Sriskandarajah N, Vicente C, Golam SM. The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada. All Asthma Clin Immunol. 2021;17:108.
Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax. 2000;55(8):650-6.
Saito T, Hasunuma T. Safety and tolerability of high-dose budesonide/formoterol via Turbuhaler® in Japanese patients with asthma: a randomized, double-blind, crossover, active comparator-controlled, phase III study. Clin Drug Investig. 2012;32:51-61.
El Baou C, Di Santostefano RL, Alfonso-Cristancho R, Suarez EA, Stempel D, et al. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med.2017;17(1):31.
Murayama N, Asai K, Murayama K, Doi S, Kameda M. Dry Powder and budesonide inhalation suspension deposition rates in asthmatic airway-obstruction regions. J Drug Deliv. 2019;2019:3921426.
Hejazi ME, Shafiifar A, Mashayekhi S, Sattari M. Evaluation of proper usage of glucocorticosteroid inhalers and their adverse effects in asthmatic patients. Tanaffos. 2016;15(1):9-16.
Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim Care Respir J. 2007;16(4):207-14.
Downloads
Published
How to Cite
Issue
Section
